Lonsurf

disease progression after 2 or more HER2/neu-targeted therapy, oxaliplatin, Stomach Neoplasms + 6 more
Treatment
11 FDA approvals
20 Active Studies for Lonsurf

What is Lonsurf

TipiracilThe Generic name of this drug
Treatment SummaryTipiracil is a drug used in combination with trifluridine to form TAS-102. TAS-102 is used to treat metastatic colorectal cancer that has not responded to other treatments, such as chemotherapy, anti-VEGF, or anti-EGFR therapies. Tipiracil works to increase the effectiveness of trifluridine by blocking its breakdown in the body.
Lonsurfis the brand name
image of different drug pills on a surface
Lonsurf Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Lonsurf
Tipiracil
2015
2

Approved as Treatment by the FDA

Tipiracil, otherwise called Lonsurf, is approved by the FDA for 11 uses which include Metastatic Gastric Adenocarcinoma and RAS wild-type with previous of anti-EGFR therapy .
Metastatic Gastric Adenocarcinoma
Used to treat Metastatic Gastric Adenocarcinoma in combination with Trifluridine
RAS wild-type with previous of anti-EGFR therapy
Used to treat RAS wild-type with previous of anti-EGFR therapy in combination with Trifluridine
oxaliplatin
Used to treat previous treatment with fluoropyrimidine, oxaliplatin and irinotecan in combination with Trifluridine
Metastatic Colorectal Cancer (CRC)
Used to treat Metastatic Colorectal Cancer (CRC) in combination with Trifluridine
previously treated with anti-VEGF
Used to treat previously treated with anti-VEGF in combination with Trifluridine
Colorectal Cancer
Used to treat Metastatic Colorectal Cancer (CRC) in combination with Trifluridine
Pharmacotherapy
Used to treat previously treated with irinotecan chemotherapy in combination with Trifluridine
disease progression after 2 or more HER2/neu-targeted therapy
Used to treat disease progression after 2 or more HER2/neu-targeted therapy in combination with Trifluridine
Metastatic Gastroesophageal Junction Adenocarcinoma
Used to treat Metastatic Gastroesophageal Junction Adenocarcinoma in combination with Trifluridine
at least two prior systemic chemotherapy regimens
Used to treat at least two prior systemic chemotherapy regimens in combination with Trifluridine
Stomach Neoplasms
Used to treat Metastatic Gastric Adenocarcinoma in combination with Trifluridine

Effectiveness

How Lonsurf Affects PatientsTipiracil stops the body from changing trifluridine into a form that does not work. This lets trifluridine to be more effective in the body. Tipiracil also prevents the enzyme thymidine phosphorylase from working. This enzyme causes blood vessel growth, so blocking it can help treat some diseases.
How Lonsurf works in the bodyTipiracil keeps the active component of trifluridine in the body for longer, making it more effective. It also helps to reduce the presence of a protein linked to the growth of tumors, which can make them more aggressive. This means that tipiracil can help stop tumor growth or even shrink tumors.

When to interrupt dosage

The measure of Lonsurf is contingent upon the specified condition. The amount of dosage corresponds to the technique of delivery (e.g. Tablet - Oral or Oral) outlined in the table beneath.
Condition
Dosage
Administration
disease progression after 2 or more HER2/neu-targeted therapy
, 8.19 mg, 6.14 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral
oxaliplatin
, 8.19 mg, 6.14 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral
Stomach Neoplasms
, 8.19 mg, 6.14 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral
Metastatic Gastroesophageal Junction Adenocarcinoma
, 8.19 mg, 6.14 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral
at least two prior systemic chemotherapy regimens
, 8.19 mg, 6.14 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral
Pharmacotherapy
, 8.19 mg, 6.14 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral
RAS wild-type with previous of anti-EGFR therapy
, 8.19 mg, 6.14 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral
previously treated with anti-VEGF
, 8.19 mg, 6.14 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral
Colorectal Cancer
, 8.19 mg, 6.14 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral

Warnings

Common Lonsurf Drug Interactions
Drug Name
Risk Level
Description
Lonsurf Toxicity & Overdose RiskTAS-102 is a toxic drug that can cause decreased production of white blood cells, red blood cells, and platelets, as well as fever from low white blood cell count. Animal studies have also found this drug to potentially be toxic to embryos and fetuses.
image of a doctor in a lab doing drug, clinical research

Lonsurf Novel Uses: Which Conditions Have a Clinical Trial Featuring Lonsurf?

49 active studies are presently examining the efficacy of Lonsurf in the management of Metastatic Colorectal Cancer.
Condition
Clinical Trials
Trial Phases
at least two prior systemic chemotherapy regimens
0 Actively Recruiting
Metastatic Gastroesophageal Junction Adenocarcinoma
18 Actively Recruiting
Phase 2, Phase 1, Not Applicable, Early Phase 1, Phase 3
Pharmacotherapy
0 Actively Recruiting
oxaliplatin
0 Actively Recruiting
RAS wild-type with previous of anti-EGFR therapy
0 Actively Recruiting
previously treated with anti-VEGF
0 Actively Recruiting
Colorectal Cancer
47 Actively Recruiting
Phase 2, Phase 1, Phase 3, Not Applicable, Early Phase 1
disease progression after 2 or more HER2/neu-targeted therapy
0 Actively Recruiting
Stomach Neoplasms
0 Actively Recruiting

Lonsurf Reviews: What are patients saying about Lonsurf?

3.7Patient Review
12/14/2016
Lonsurf for Colon and Rectal Cancer that has Spread to Another Area
I experienced hair loss after the first round of treatment, which was frustrating. However, the medication was easy to take with few other side effects.
1.7Patient Review
12/29/2017
Lonsurf for Colon and Rectal Cancer that has Spread to Another Area
The side effects of this treatment were really terrible. It completely ruined my sense of taste and made it hard to eat. I also felt incredibly flu-like, with a messed up digestive system and regular nausea and vomiting. Overall, I don't think the benefits are worth the cost.
1.3Patient Review
3/15/2016
Lonsurf for Colon and Rectal Cancer that has Spread to Another Area
Unfortunately, this medication has been very tough on my stomach. I've had a lot of pain and bloating as well as gas. After the first treatment, my CEA went from 298 to 990. However, I am starting my second round of treatment and am hopeful that it will start to lower my count again.
1.3Patient Review
6/15/2016
Lonsurf for Colon and Rectal Cancer that has Spread to Another Area
Lonsurf was totally ineffective and it decreased the quality of my life significantly.
1Patient Review
7/18/2021
Lonsurf for Colon and Rectal Cancer that has Spread to Another Area
My wife's health rapidly declined after she started taking this medication. We fought for a CT scan against our oncologist's advice and found that the cancer was growing everywhere. I expressed my dissatisfaction with her doctor.
1Patient Review
12/23/2021
Lonsurf for Colon and Rectal Cancer that has Spread to Another Area
I would not recommend this treatment to anyone. My husband died after taking it and he was only getting worse with each cycle.
1Patient Review
7/12/2022
Lonsurf for Colon and Rectal Cancer that has Spread to Another Area
Avoid this treatment at all cost! I started taking it and just a few days later ended up in the ER in severe pain. My quality of life decreased drastically; I was short of breath, depressed, and my thinking changed. All of this in such a short time after starting the treatment.
1Patient Review
2/23/2020
Lonsurf for Colon and Rectal Cancer that has Spread to Another Area
I metastatic colon and rectal cancer to my lungs, and this treatment unfortunately didn't work for me. My hair started falling out and the tumor grew. I'm now on intravenous chemotherapy.
1Patient Review
12/23/2021
Lonsurf for Colon and Rectal Cancer that has Spread to Another Area
I am so incredibly saddened by the death of my husband. He started taking Lonsurf and within weeks was sleeping all the time, to the point where it became dangerous. We had no warning signs that this medication would be deadly.
1Patient Review
12/23/2021
Lonsurf for Colon and Rectal Cancer that has Spread to Another Area
My husband was living with cancer for about 10 years. He was doing well, active and working a full time job until he started taking lonsurf. He only took it for 3 cycles before he went downhill fast and passed away. If we had only read these bad experiences, he might still be alive!
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about lonsurf

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Lonsurf a last resort?

"The oncologist told the patient that the last treatment option would be to participate in a clinical trial."

Answered by AI

How long can you take Lonsurf for?

"During the first two weeks, your doctor will usually prescribe LONSURF for 10 days and then stop for two weeks."

Answered by AI

Can Lonsurf cure cancer?

"LONSURF has been shown to help patients live longer and slow or stop the growth of cancer for a period of time."

Answered by AI

Is Lonsurf a chemotherapy?

"Lonsurf is a chemotherapy drug used to treat bowel cancer that has spread to other parts of the body."

Answered by AI

Clinical Trials for Lonsurf

Image of University of Kentucky in Lexington, United States.

Hepatic Artery Infusion Chemotherapy for Liver Cancer

18 - 99
All Sexes
Lexington, KY
The goal of this clinical trial is to help learn about the safety and feasibility of hepatic artery infusion chemotherapy for those who have colorectal liver metastases, both resectable and unresectable, or unresectable intrahepatic cholangiocarcinoma. The main questions it aims to answer are: * safety and feasibility of installing a pump that deliveries chemotherapy to the hepatic artery (the blood vessel that supplies blood to the liver) * help learn more about the safety of patients having pump refills at home or a local clinic versus having it routinely done at the hospital Participants will have surgery to install a pump which is a standard surgical procedure. After surgery, participants will select to either receive treatment at the hospital facility or with a community oncologist that will provide cancer care to participants close to home, rather than in a large hospital or academic medical center. The main treatment on study will last about 3-4 months.
Phase 2
Waitlist Available
University of KentuckyMichael Cavnar, MD
Image of RJ Zuckerberg in Lake Success, United States.

Implantable Microdevice for Colorectal Cancer

18+
All Sexes
Lake Success, NY
Microdevices have been used to ascertain in vivo drug response, which can lead to improved cancer treatment delivery; however, they have not been evaluated for liver tumors. This is a prospective, phase 1 safety study of percutaneous placement and surgical retrieval of a microdevice in patients with liver metastasis from colorectal cancer. The device will be implanted percutaneously 3-5 days prior to scheduled resection of colorectal liver metastasis (CLM) and then removed en bloc with the tumor. Patients will be monitored to ensure that the device's placement and retrieval does not result in increased complication rates within 14 days of surgery. To assess feasibility, the tissue surrounding the microdevice will be analyzed to assess the diffusion of the drugs from the device into the tissue and whether the therapeutic effect of diffusing chemotherapy +/- immune-modulating drugs has an impact on the surrounding tissue.
Phase < 1
Waitlist Available
RJ Zuckerberg
Image of RJ Zuckerberg in Lake Success, United States.

Nelitolimod for Colorectal Cancer

18+
All Sexes
Lake Success, NY
Nelitolimod is a classC toll-like receptor 9 (TLR9) agonist that binds to TLR9 receptors on myeloid-derived suppressor cells(MDSCs) and helps reshape the tumor microenvironment (TME) and promote antitumor immunity. Investigators hypothesize that Nelitolimod can induce antitumor immune response in CRLM when administered regionally to the liver via a TriNav Pressure Enabled Drug Delivery (PEDD) catheter without compromising surgical feasibility or patient safety. The study objective is to investigate the feasibility and safety of an innovative immunotherapeutic approach for patients with CRLM designed to overcome the immunosuppressive TME in CRLM. Investigators hypothesize that this investigational neoadjuvant treatment will be well tolerated and will not prevent patients from undergoing successful, safe CRLM liver resections. Investigators will assess the safety and feasibility of Nelitolimod given via TriNav PEDD in 10 patients with CRLM prior to liver resection. Patients will receive standard treatment with chemotherapy and then undergo placement of the PEDD catheter. Patients will then receive 3 doses of Nelitolimod before undergoing liver resection.
Phase < 1
Waitlist Available
RJ Zuckerberg
Image of START Midwest in Grand Rapids, United States.

BNT314 + BNT327 + Chemotherapy for Colorectal Cancer

18+
All Sexes
Grand Rapids, MI
This randomized, multi-site, three-part study will test a new treatment called BNT314, which is designed to help the body's immune system fight cancer in combination with another new treatment (BNT327, which is an immune checkpoint inhibitor) and chemotherapy in participants with metastatic colorectal cancer (mCRC). This study will enroll participants with microsatellite stable or mismatch repair proficient (MSS/pMMR) mCRC who did not respond well to their first schema of chemotherapy. In one part of the study (i.e., Part B) mCRC participants will be enrolled, who have not received any systemic therapy before for their cancer.
Phase 1 & 2
Recruiting
START MidwestBioNTech Responsible PersonBioNTech SE
Have you considered Lonsurf clinical trials? We made a collection of clinical trials featuring Lonsurf, we think they might fit your search criteria.Go to Trials
Image of University of Alabama at Birmingham in Birmingham, United States.

ProAgio for Colorectal Cancer

18+
All Sexes
Birmingham, AL
This is an open-label Phase I/Ib dose-escalation, dose-expansion clinical trial of the safety, pharmacokinetics and clinical activity of ProAgio combined with 5-fluorouracil, irinotecan (FOLFIRI) and bevacizumab for untreated advanced/metastatic CRC. The study will use an Accelerated titration BOIN design in Phase I to determine the recommended RP2D of ProAgio with FOLFIRI + bevacizumab. The trial will estimate the RP2D of ProAgio when combined with FOLFIRI + bevacizumab, starting from 2 dose levels lower than the estimated RP2D of ProAgio alone. Accelerated titration BOIN design will enroll patients with the 4 combination dose levels. Subjects will be selected based on following criteria: previously untreated advanced/metastatic CRC, ECOG performance status (0-1), and adequate organ functions. Subjects with recent surgeries, history of recent thromboembolic events or significant cardiovascular disease will be excluded. Once the MTD and RP2D of ProAgio with FOLFIRI have been identified, an expansion cohort of 12 subjects with advanced/metastatic CRC will begin. The purpose of the expansion cohort is to confirm the safety of the regimen and provide preliminary data on the activity of ProAgio + FOLFIRI + bevacizumab.
Phase 1
Recruiting
University of Alabama at BirminghamMidun Malla, MD
Image of Hope And Healing Cancer Services /ID# 271562 in Hinsdale, United States.

Telisotuzumab Adizutecan + Combination Therapy for Colorectal Cancer

18+
All Sexes
Hinsdale, IL
CRC is the third most common type of cancer diagnosed worldwide with developed countries at highest risk. The purpose of this study is to assess adverse events and change in disease activity when telisotuzumab adizutecan is given in combination with oxaliplatin, fluorouracil (5FU), leucovorin (LV) (FOLFOX), and bevacizumab or panitumumab. Telisotuzumab adizutecan is an investigational drug being developed for the treatment of mCRC. Fluorouracil and leucovorin are drugs approved for the treatment of mCRC. This study will be divided into two stages, with the first stage treating participants with increasing doses of telisotuzumab adizutecan with FOLFOX and bevacizumab or 5FU/LV and panitumumab until the dose reached is tolerable and expected to be efficacious. Participants will then be randomized into 3 groups called treatment arms where one group will receive one of two optimized doses of telisotuzumab adizutecan from the dose escalation phase with FOLFOX and bevacizumab or 5FU/LV and panitumumab, or a comparator of FOLFOX and bevacizumab or panitumumab. Approximately 390 adult participants with mCRC will be enrolled in the study in 100 sites worldwide. In the dose escalation stage participants will be treated with increasing intravenous (IV) doses of telisotuzumab adizutecan with FOLFOX and bevacizumab or 5FU/LV and panitumumab until the dose reached is tolerable and expected to be efficacious. In the dose optimization stage participants will be receive FOLFOX or receive 5FU/LV, but with one of two optimized doses of telisotuzumab adizutecan, or a comparator of FOLFOX and bevacizumab/pantitumumab. The study will run for a duration of approximately 6 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.
Phase 2
Recruiting
Hope And Healing Cancer Services /ID# 271562 (+10 Sites)ABBVIE INC.AbbVie
Have you considered Lonsurf clinical trials? We made a collection of clinical trials featuring Lonsurf, we think they might fit your search criteria.Go to Trials
Image of Springfield Clinic /ID# 268666 in Springfield, United States.

ABBV-400 vs Standard Treatment for Colorectal Cancer

18+
All Sexes
Springfield, IL
Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide and in China. The purpose of this study is to assess adverse events disease activity when comparing intravenously (IV) infused telisotuzumab adizutecan to trifluridine and tipiracil (LONSURF) oral tablets plus IV infused bevacizumab in adult participants with c-Met protein above cutoff level refractory metastatic colorectal cancer (mCRC). Telisotuzumab adizutecan is an investigational drug being developed for the treatment of CRC. Participants are put into treatment arms as part of 2 stages. Each treatment arm in stage 1 receives a different dose of telisotuzumab adizutecan. Each treatment arm in stage 2 receives the optimal dose of telisotuzumab adizutecan or LONSURF plus bevacizumab. Up to approximately 460 adult participants with c-Met protein above cutoff level refractory mCRC, will be enrolled in the study in approximately 160 sites in 15-20 countries. In stage 1, participants will receive intravenously (IV) infused telisotuzumab adizutecan dose A or B. In stage 2, participants will receive the optimal dose of IV infused telisotuzumab adizutecan or the standard of care (SOC), LONSURF oral tablets plus IV infused bevacizumab. The total study duration will be approximately 4 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.
Phase 3
Recruiting
Springfield Clinic /ID# 268666 (+26 Sites)ABBVIE INC.AbbVie
Have you considered Lonsurf clinical trials? We made a collection of clinical trials featuring Lonsurf, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security